Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base

被引:6
作者
Cohen, Andrew J. [1 ]
Packiam, Vignesh [1 ]
Nottingham, Charles [1 ]
Steinberg, Gary [1 ]
Smith, Norm D. [1 ]
Patel, Sanjay [2 ]
机构
[1] Univ Chicago Med, Dept Surg, Urol Sect, Chicago, IL 60637 USA
[2] Univ Oklahoma, Dept Urol, Oklahoma City, OK USA
关键词
Adenocarcinoma; Bladder cancer; Prognosis; Squamous; Small cell; SMALL-CELL CARCINOMA; UROTHELIAL CARCINOMA; NEOADJUVANT CHEMOTHERAPY; PARTIAL CYSTECTOMY; RADICAL CYSTECTOMY; URINARY-BLADDER; RISK-FACTORS; SURVIVAL; ADENOCARCINOMAS; DIFFERENTIATION;
D O I
10.1016/j.urolonc.2016.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine patient and pathologic characteristics as well as outcomes for patients with clinically localized, nonurothelial histology bladder cancer. Materials and methods: Using the National Cancer Data Base, we identified patients between 2000 and 2010 diagnosed with bladder cancer as their only malignancy undergoing definitive surgical management. Patients were characterized as urothelial (n = 13,442), squamous (n = 789), small cell (n = 124), adenocarcinoma (n = 789), or other histology (n = 499). Patient and pathologic characteristics were compared across histologic subtypes. We also evaluated for incidence of T and N upstaging. Survival analysis was performed using the Kaplan-Meier method. Multivariate survival analysis was performed to identify predictors of adverse overall survival. Results: Patients with nonurothelial histology were more likely to be African-American, treated at academic medical centers, and of younger age (all P < 0.05). Among those with nonurothelial histology, 55.4% of patients presenting with clinical stage T1 or less had their tumor upstaged during definitive surgical treatment compared to 42.7% of those with urothelial carcinoma. Squamous histology incurred the highest upgrading rate of 61.8%. Five-year survival varied by subtype, with universally decreased survival for those upstaged. Among nonurothelial histology, overall 5-year survival was 32.4% (95% CI: 28.8%-36.2%) vs. 46.0% (95% CI: 42.3%-49.6%) for those upstaged and not upstaged, respectively. Neoadjuvant therapy is used infrequently in this population. Conclusion: We present the largest survival analysis of various rare subtypes of bladder cancer to date. Patients with nonurothelial bladder cancer have significantly higher rate of upstaging at cystectomy and with this a worsened overall survival. Aggressive treatment should be strongly considered for nonurothelial cancers when identified. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:34.e1 / 34.e8
页数:8
相关论文
共 29 条
[21]  
Saadat SH, 2011, UROL J, V8, P291
[22]   An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma [J].
Sánchez-Ortiz, RF ;
Huang, WC ;
Mick, R ;
Van Arsdalen, KN ;
Wein, AJ ;
Malkowicz, SB .
JOURNAL OF UROLOGY, 2003, 169 (01) :110-115
[23]   Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients [J].
Stein, JP ;
Lieskovsky, G ;
Cote, R ;
Groshen, S ;
Feng, AC ;
Boyd, S ;
Skinner, E ;
Bochner, B ;
Thangathurai, D ;
Mikhail, M ;
Raghavan, D ;
Skinner, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :666-675
[24]   Urothelial carcinoma with divergent histologic differentiation (Mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection [J].
Wasco, Matthew J. ;
Daignault, Stephanie ;
Zhang, Yingxi ;
Kunju, Lakshmi Priya ;
Kinnaman, Michael ;
Braun, Thomas ;
Lee, Cheryl T. ;
Shah, Rajal B. .
UROLOGY, 2007, 70 (01) :69-74
[25]   Comprehensive molecular characterization of urothelial bladder carcinoma [J].
Weinstein, John N. ;
Akbani, Rehan ;
Broom, Bradley M. ;
Wang, Wenyi ;
Verhaak, Roeland G. W. ;
McConkey, David ;
Lerner, Seth ;
Morgan, Margaret ;
Creighton, Chad J. ;
Smith, Carolyn ;
Kwiatkowski, David J. ;
Cherniack, Andrew D. ;
Kim, Jaegil ;
Pedamallu, Chandra Sekhar ;
Noble, Michael S. ;
Al-Ahmadie, Hikmat A. ;
Reuter, Victor E. ;
Rosenberg, Jonathan E. ;
Bajorin, Dean F. ;
Bochner, Bernard H. ;
Solit, David B. ;
Koppie, Theresa ;
Robinson, Brian ;
Gordenin, Dmitry A. ;
Fargo, David ;
Klimczak, Leszek J. ;
Roberts, Steven A. ;
Au, Jessie ;
Laird, Peter W. ;
Hinoue, Toshinori ;
Schultz, Nikolaus ;
Ramirez, Ricardo ;
Hansel, Donna ;
Hoadley, Katherine A. ;
Kim, William Y. ;
Damrauer, Jeffrey S. ;
Baylin, Stephen B. ;
Mungall, Andrew J. ;
Robertson, A. Gordon ;
Chu, Andy ;
Kwiatkowski, David J. ;
Sougnez, Carrie ;
Cibulskis, Kristian ;
Lichtenstein, Lee ;
Sivachenko, Andrey ;
Stewart, Chip ;
Lawrence, Michael S. ;
Getz, Gad ;
Lander, Eric ;
Gabriel, Stacey B. .
NATURE, 2014, 507 (7492) :315-322
[26]  
Williams Christopher R, 2015, Rev Urol, V17, P46
[27]   Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder [J].
Wright, Jonathan L. ;
Porter, Michael P. ;
Li, Christopher I. ;
Lange, Paul H. ;
Lin, Daniel W. .
CANCER, 2006, 107 (04) :721-728
[28]   Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy [J].
Xylinas, Evanguelos ;
Rink, Michael ;
Novara, Giacomo ;
Green, David A. ;
Clozel, Thomas ;
Fritsche, Hans-Martin ;
Guillonneau, Bertrand ;
Lotan, Yair ;
Kassouf, Wassim ;
Tilki, Derya ;
Babjuk, Marek ;
Karakiewicz, Pierre I. ;
Montorsi, Francesco ;
Abdennabi, Joual ;
Trinh, Quoc D. ;
Svatek, Robert S. ;
Scherr, Douglas S. ;
Zerbib, Marc ;
Shariat, Shahrokh F. .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (03) :1027-1034
[29]   Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience [J].
Yu, Bin ;
Zhou, Jin ;
Cai, Hongzhou ;
Xu, Ting ;
Xu, Zicheng ;
Zou, Qing ;
Gu, Min .
BMC UROLOGY, 2015, 15